Drug Search Results

Pefloxacin

Alternative Names: pefloxacin
Latest Update: 2024-08-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: DNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: CHRU de TOURS
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pefloxacin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success

Recent News Events

Date	Type	Title
08/01/2024	PubMed	Insight into Fe-O-Bi electron migration channel in MIL-53(Fe)/Bi4O5I2 Z-scheme heterojunction for efficient photocatalytic decontamination.
04/25/2024	PubMed	Typhoid fever in children in Goroka, Papua New Guinea.
04/09/2024	PubMed	Promoting oxygen vacancies utility for tetracycline degradation via peroxymonosulfate activation by reduced Mg-doped Co3O4: Kinetics and key role of electron transfer pathway.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions